GSK in nicotine patch link-up with Taisho
GlaxoSmithKline and Taisho Pharmaceutical have agreed to jointlydevelop and market smoking cessation products in Japan. Under the terms of the deal, GSK's Japanese unit will supply nicotine patches, which Taisho will sell and distribute, the former said.
The move comes soon after Pharmacia and Takeda Chemical Industries reached an agreement in which the latter has exclusive distribution rights in Japan for the Nicorette brand of smoking cessation products. (Marketletter May 21). Pharmacia has just received Japanese approval for over-the-counter use of Nicorette.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze